MedTrace Logo

Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)

NCT00106704 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 441

Last updated 2015-07-01

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with Type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Comparator: Sitagliptin

sitagliptin 10 mg tablet, once daily for 54 weeks

DRUG

Comparator: Placebo

Placebo oral tablet once daily for 24 weeks

DRUG

Comparator: Pioglitazone

Pioglitazone 30 mg tablet once daily for 30 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-06-30
Completion
2007-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00106704 on ClinicalTrials.gov